{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:16:36Z","timestamp":1787498196741,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA045618"],"award-info":[{"award-number":["K01DA045618"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U24AA022002"],"award-info":[{"award-number":["U24AA022002"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine Reports"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.pmedr.2023.102138","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T02:13:43Z","timestamp":1676254423000},"page":"102138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-8111","authenticated-orcid":false,"given":"Haesuk","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Hern\u00e1ndez-Con","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Goodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roniel","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pmedr.2023.102138_b0005","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","article-title":"Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis","volume":"96","author":"Amoako","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.pmedr.2023.102138_b0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.pmedr.2023.102138_b0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program","volume":"75","author":"Butner","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.pmedr.2023.102138_b0020","unstructured":"Centers for Disease Control and Prevention, 2017. Increase in hepatitis C infections linked to worsening opioid crisis. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2017\/hepatitis-c-and-opioid-injection.html."},{"key":"10.1016\/j.pmedr.2023.102138_b0025","unstructured":"Centers for Disease Control and Prevention, 2021. New estimates reveal declines in hepatitis C treatment in the U.S. between 2005 and 2020. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2021\/2014-2020-hepatitis-c-treatment-estimates.html."},{"key":"10.1016\/j.pmedr.2023.102138_b0035","series-title":"Internet, Phone, Mail, and Mixed Mode Surveys: The Tailored Design Method","author":"Dillman","year":"2014"},{"key":"10.1016\/j.pmedr.2023.102138_b0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jhep.2013.11.014","article-title":"The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010","volume":"60","author":"Ditah","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.pmedr.2023.102138_b0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/medhum-2017-011186","article-title":"Health-related shame: an affective determinant of health?","volume":"43","author":"Dolezal","year":"2017","journal-title":"Med. Humanit."},{"key":"10.1016\/j.pmedr.2023.102138_b0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pmedr.2023.102138_b0055","first-page":"41","article-title":"A Modifiable Barrier to Hepatitis C Virus Elimination in Rhode Island: The Prior Authorization Process for Direct-Acting Antiviral Agents","volume":"103","author":"Duryea","year":"2020","journal-title":"Rhode Island Med. J."},{"key":"10.1016\/j.pmedr.2023.102138_b0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pmedr.2023.102138_b0070","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.drugpo.2015.07.007","article-title":"International Network for Hepatitis in Substance U. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.pmedr.2023.102138_b0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","article-title":"Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy","volume":"47","author":"Grebely","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.pmedr.2023.102138_b0065","unstructured":"Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), 2020. About GHAPP. Accessed 18 October 2021. https:\/\/www.ghapp.org\/about."},{"key":"10.1016\/j.pmedr.2023.102138_b0080","doi-asserted-by":"crossref","first-page":"ofy001","DOI":"10.1093\/ofid\/ofy001","article-title":"Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies","volume":"5","author":"Grebely","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.pmedr.2023.102138_b0030","unstructured":"Harvard Law School Center for Health Law and Policy Intervention, 2022. Hepatitis C: State of Medicaid Access National Summary Report. Accessed 15 February 2023. https:\/\/stateofhepc.org\/wp-content\/uploads\/2022\/06\/State-of-Hep-C-Report_2022-1.pdf."},{"key":"10.1016\/j.pmedr.2023.102138_b0085","doi-asserted-by":"crossref","first-page":"108460","DOI":"10.1016\/j.jsat.2021.108460","article-title":"Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia","volume":"127","author":"Heard","year":"2021","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.pmedr.2023.102138_b0090","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jvh.13278","article-title":"Patient and provider-level barriers to hepatitis C screening and linkage to care: A mixed-methods evaluation","volume":"27","author":"Higashi","year":"2020","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.pmedr.2023.102138_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.02.022","article-title":"Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse","volume":"13","author":"Ho","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pmedr.2023.102138_b0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hep.30171","article-title":"Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period?","volume":"69","author":"Jain","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pmedr.2023.102138_b0105","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jgh.15228","article-title":"Barriers to hepatitis C direct-acting antiviral therapy among HIV\/hepatitis C virus-coinfected persons","volume":"36","author":"Jatt","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.pmedr.2023.102138_b0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amepre.2021.03.011","article-title":"Decreases in hepatitis C testing and treatment during the COVID-19 pandemic","volume":"61","author":"Kaufman","year":"2021","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.pmedr.2023.102138_b0115","doi-asserted-by":"crossref","first-page":"833","DOI":"10.15585\/mmwr.mm6839a1","article-title":"National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization \u2013 United States, 2000\u20132015","volume":"68","author":"Ko","year":"2019","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.pmedr.2023.102138_b0120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.pmedr.2023.102138_b0125","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1716871","article-title":"Hepatitis C in injection-drug users \u2013 a hidden danger of the opioid epidemic","volume":"378","author":"Liang","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pmedr.2023.102138_b0130","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jvh.13119","article-title":"Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study","volume":"26","author":"Litwin","year":"2019","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.pmedr.2023.102138_b0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.aohep.2018.06.001","article-title":"Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic","volume":"18","author":"Malespin","year":"2019","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.pmedr.2023.102138_b0140","doi-asserted-by":"crossref","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","article-title":"Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists\u2014The practitioner experience","volume":"206","author":"Marshall","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pmedr.2023.102138_b0145","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/261472","article-title":"Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre","volume":"2010","author":"Moussalli","year":"2010","journal-title":"Gastroenterol Res. Pract."},{"key":"10.1016\/j.pmedr.2023.102138_b0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1155\/2011\/810108","article-title":"Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada","volume":"25","author":"Myles","year":"2011","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.pmedr.2023.102138_b0155","unstructured":"National Library of Medicine (U.S.). Study of Oral Treatments for Hepatitis C (PRIORITIZE). Identifier NCT02786537. Accessed 18 October 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02786537?term=NCT02786537&rank=1."},{"key":"10.1016\/j.pmedr.2023.102138_b0160","unstructured":"National Library of Medicine (U.S.), 2021. HCV-TARGET \u2013 Hepatitis C Therapeutic Registry and Research Network. Identifier NCT01474811. Accessed 18 October 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01474811."},{"key":"10.1016\/j.pmedr.2023.102138_b0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/1060028018824988","article-title":"Impact of substance use disorder on the rate of sustained virological response in veterans with chronic hepatitis C treated with direct-acting antivirals","volume":"53","author":"Ottman","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pmedr.2023.102138_b0170","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pmedr.2023.102138_b0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/hex.13400","article-title":"Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review","volume":"25","author":"Paisi","year":"2022","journal-title":"Health Expect"},{"key":"10.1016\/j.pmedr.2023.102138_b0180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/hep4.1634","article-title":"Direct-acting antiviral treatment use remains low among florida medicaid beneficiaries with chronic hepatitis C","volume":"5","author":"Park","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.pmedr.2023.102138_b0185","series-title":"Making Sense of Factor Analysis","author":"Pett","year":"2003"},{"key":"10.1016\/j.pmedr.2023.102138_b0190","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/apc.2021.0087","article-title":"Disparities in treatment with direct-acting hepatitis C Virus antivirals persist among adults coinfected with HIV and hepatitis C virus in US Clinics, 2010\u20132018","volume":"35","author":"Simoncini","year":"2021","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.pmedr.2023.102138_b0195","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0b013e31824c0dea","article-title":"A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States","volume":"47","author":"Tinsley","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.pmedr.2023.102138_b0200","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1093\/infdis\/jiaa574","article-title":"We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States","volume":"222","author":"Trooskin","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pmedr.2023.102138_b0205","first-page":"E201","article-title":"Family medicine\u2013directed hepatitis C care and barriers to treatment: a mixed-methods study","volume":"9","author":"von Aesch","year":"2021","journal-title":"Canad. Med. Assoc. Open Access J."},{"key":"10.1016\/j.pmedr.2023.102138_b0210","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1007\/s11606-022-07628-9","article-title":"Integrating management of hepatitis C infection into primary care: the key to hepatitis C elimination efforts","volume":"37","author":"Wang","year":"2022","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.pmedr.2023.102138_b0215","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pmedr.2023.102138_b0220","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/hiv.12023","article-title":"Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV\/HCV-coinfected patients: role of comorbidities and physicians\u2019 perceptions","volume":"14","author":"Winnock","year":"2013","journal-title":"HIV Med"},{"key":"10.1016\/j.pmedr.2023.102138_b0225","unstructured":"World Health Organization (WHO), 2017. Hepatitis C. Accessed 7 February 2022. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/."},{"key":"10.1016\/j.pmedr.2023.102138_b0230","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s10620-019-05877-z","article-title":"Provider perceptions of hepatitis C treatment adherence and initiation","volume":"65","author":"Zhang","year":"2020","journal-title":"Dig. Dis. Sci."}],"container-title":["Preventive Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335523000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211335523000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:09:54Z","timestamp":1761923394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211335523000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":46,"alternative-id":["S2211335523000293"],"URL":"https:\/\/doi.org\/10.1016\/j.pmedr.2023.102138","relation":{},"ISSN":["2211-3355"],"issn-type":[{"value":"2211-3355","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmedr.2023.102138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102138"}}